Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16854)	5/10/2004 9:58:43 PM
From: aknahow	Respond to of 17367

Bluegreen, I thought i would be able to figure out Raptiva sales from the earnings release. wow, how little I knew. I am so smart, I knew the share of net profits would not show up contract revenue, So I looked at other income. It's not there! It's not anywhere. So what can I say except I'm so glad I'm short some shares, because I owe them to a family member. Three months ended March 31, -------------------- 2004 2003 -------- -------- Revenues: License and collaborative fees $ 155 $ 1,155 Contract and other revenue 15 2,009 -------- -------- Total revenues 170 3,164 -------- -------- Operating costs and expenses: Research and development 13,015 12,836 General and administrative 3,935 3,306 Collaboration arrangement (benefit) 3,238 (255) -------- -------- Total operating costs and expenses 20,188 15,887 -------- -------- Loss from operations (20,018) (12,723) Other income (expense): Investment and interest income 194 113 Interest expense (340) (486) Other income (expense) (4) 2 -------- -------- Net loss $(20,168) $(13,094) ======== ======== Basic and diluted net loss per common share $ (0.24) $ (0.18) ======== ======== Shares used in computing basic and diluted net loss per common share 84,171 71,843 ======== ======== Amounts derived from the Company's audited financial statements appearing in the Annual Report on Form 10-K for the year ended December 31, 2003 as filed with the Securities and Exchange Commission. ------------------------------------------------------------------------ Contact: XOMA Ltd. Laura Zobkiw, 510-204-7200 (Corp. Comm./IR) Peter Davis, 510-204-7200 (CFO)